Class of chemical compounds
Amides of lysergic acid are collectively known as lysergamides , and include a number of compounds with potent agonist and/or antagonist activity at various serotonin and dopamine receptors . Lysergamides contain an embedded tryptamine structure, and as a result can produce similar, often psychedelic , effects to those of the true tryptamines. [ 1] [ 2] [ 3] [ 4] [ 5] [ 6] [ 7] [ 8] [ 9] [ 10] [ 11] [ 12] [ 13] [ 14] [ 15]
General structure of Lysergamides
Lysergamides, tabulated by structure
Structure
Name
CAS number
R1
R6
R2
R3
Other
LSA / LAA
478-94-4
H
CH3
H
H
-
DAM-57
4238-84-0
H
CH3
CH3
CH3
-
Ergometrine (Ergonovine)
60-79-7
H
CH3
CH(CH3 )CH2 OH
H
-
Ergotamine
113-15-5
H
CH3
--
C17 H18 N2 O4
-
Methergine
113-42-8
H
CH3
CH(CH2 CH3 )CH2 OH
H
-
Methysergide
361-37-5
CH3
CH3
CH(CH2 CH3 )CH2 OH
H
-
Amesergide
121588-75-8
CH(CH3 )2
CH3
C6 H11
H
-
LY-215840
137328-52-0
CH(CH3 )2
CH3
C5 H8 OH
H
-
Cabergoline
81409-90-7
H
H2 C=CH-CH2
CONHCH2 CH3
CH2 CH2 CH2 N(CH3 )2
-
LAE-32
478-99-9
H
CH3
CH2 CH3
H
-
LAiP
H
CH3
CH(CH3 )2
H
-
LAtB
H
CH3
C(CH3 )3
H
-
LAcB
H
CH3
(CH2 )4
H
-
Cepentil
H
CH3
(CH2 )5
H
-
LSB
137765-82-3
H
CH3
CH(CH3 )CH2 CH3
H
-
LSP
H
CH3
CH(CH2 CH3 )CH2 CH3
H
-
DAL
H
CH3
H2 C=CH-CH2
H2 C=CH-CH2
-
MIPLA
100768-08-9
H
CH3
CH(CH3 )2
CH3
-
EIPLA
H
CH3
CH(CH3 )2
CH2 CH3
-
ECPLA
H
CH3
C3 H5
CH2 CH3
-
ETFELA
H
CH3
CH2 CF3
CH2 CH3
-
LAMPA
40158-98-3
H
CH3
CH2 CH2 CH3
CH3
-
EPLA
H
CH2 CH3
CH2 CH2 CH3
CH3
-
LSD / LAD
50-37-3
H
CH3
CH2 CH3
CH2 CH3
-
ETH-LAD
65527-62-0
H
CH2 CH3
CH2 CH3
CH2 CH3
-
PARGY-LAD
H
HC≡C−CH2
CH2 CH3
CH2 CH3
-
AL-LAD
65527-61-9
H
H2 C=CH-CH2
CH2 CH3
CH2 CH3
-
PRO-LAD
65527-63-1
H
CH2 CH2 CH3
CH2 CH3
CH2 CH3
-
IP-LAD
H
CH(CH3 )2
CH2 CH3
CH2 CH3
-
CYP-LAD[ 16]
H
C3 H5
CH2 CH3
CH2 CH3
-
BU-LAD
96930-87-9
H
CH2 CH2 CH2 CH3
CH2 CH3
CH2 CH3
-
FLUORETH-LAD [ 17]
H
CH2 CH2 F
CH2 CH3
CH2 CH3
-
ALD-52
3270-02-8
COCH3
CH3
CH2 CH3
CH2 CH3
-
1P-LSD
2349358-81-0
COCH2 CH3
CH3
CH2 CH3
CH2 CH3
-
1B-LSD
2349376-12-9
COCH2 CH2 CH3
CH3
CH2 CH3
CH2 CH3
-
1V-LSD
CO(CH2 )3 CH3
CH3
CH2 CH3
CH2 CH3
-
1DD-LSD
CO(CH2 )10 CH3
CH3
CH2 CH3
CH2 CH3
-
1cP-LSD [ 18]
COC3 H5
CH3
CH2 CH3
CH2 CH3
-
1D-LSD
COC4 H5 (CH3 )2
CH3
CH2 CH3
CH2 CH3
-
1T-LSD
COC4 H3 S
CH3
CH2 CH3
CH2 CH3
-
1S-LSD
CO(CH2 )2 Si(CH3 )3
CH3
CH2 CH3
CH2 CH3
-
1P-AL-LAD
COCH2 CH3
H2 C=CH-CH2
CH2 CH3
CH2 CH3
-
1cP-AL-LAD
COC3 H5
H2 C=CH-CH2
CH2 CH3
CH2 CH3
-
1T-AL-LAD[ 19]
COC4 H3 S
H2 C=CH-CH2
CH2 CH3
CH2 CH3
-
1P-ETH-LAD
COCH2 CH3
CH2 CH3
CH2 CH3
CH2 CH3
-
1P-MIPLA
COCH2 CH3
CH3
CH(CH3 )2
CH3
-
MLD-41
4238-85-1
CH3
CH3
CH2 CH3
CH2 CH3
-
LSM-775
4314-63-0
H
CH3
CH2 CH2 -O-CH2 CH2
-
LPD-824
2385-87-7
H
CH3
(CH2 )4
-
LSD-Pip
50485-23-9
H
CH3
(CH2 )5
-
LSD-Azapane
H
CH3
(CH2 )6
-
LA-SS-Az
470666-31-0
H
CH3
CH2 (CHCH3 )2 CH2
-
2-Bromo-LSD
478-84-2
H
CH3
CH2 CH3
CH2 CH3
2-Br
12-Methoxy-LSD[ 20]
50484-99-6
H
CH3
CH2 CH3
CH2 CH3
12-OMe
13-Fluoro-LSD[ 21]
H
CH3
CH2 CH3
CH2 CH3
13-F
14-Hydroxy-LSD[ 22]
H
CH3
CH2 CH3
CH2 CH3
14-OH
^ Hofmann A (June 1959). "Psychotomimetic drugs; chemical and pharmacological aspects". Acta Physiologica et Pharmacologica Neerlandica . 8 : 240–58. PMID 13852489 .
^ US patent 2997470 , Pioch RP, "LYSERGIC ACID AMIDES", published 1956-03-05, issued 1961-08-22
^ Hoffman AJ, Nichols DE (September 1985). "Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives". Journal of Medicinal Chemistry . 28 (9): 1252–1255. doi :10.1021/jm00147a022 . PMID 4032428 .
^ Huang X, Marona-Lewicka D, Pfaff RC, Nichols DE (March 1994). "Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives". Pharmacology, Biochemistry, and Behavior . 47 (3): 667–673. doi :10.1016/0091-3057(94)90172-4 . PMID 8208787 . S2CID 16490010 .
^ Watts VJ, Lawler CP, Fox DR, Neve KA, Nichols DE, Mailman RB (April 1995). "LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors". Psychopharmacology . 118 (4): 401–409. doi :10.1007/BF02245940 . PMID 7568626 . S2CID 21484356 .
^ Nichols DE, Frescas S, Marona-Lewicka D, Kurrasch-Orbaugh DM (September 2002). "Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD)". Journal of Medicinal Chemistry . 45 (19): 4344–4349. doi :10.1021/jm020153s . PMID 12213075 .
^ Schiff PL (October 2006). "Ergot and its alkaloids" . American Journal of Pharmaceutical Education . 70 (5): 98. doi :10.5688/aj700598 . PMC 1637017 . PMID 17149427 .
^ Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A (2008). "The pharmacology of lysergic acid diethylamide: a review" . CNS Neuroscience & Therapeutics . 14 (4): 295–314. doi :10.1111/j.1755-5949.2008.00059.x . PMC 6494066 . PMID 19040555 .
^ Nichols DE (2017). "Chemistry and Structure-Activity Relationships of Psychedelics". Current Topics in Behavioral Neurosciences . 36 : 1–43. doi :10.1007/7854_2017_475 . ISBN 978-3-662-55878-2 . PMID 28401524 .
^ Brandt SD, Kavanagh PV, Westphal F, Stratford A, Elliott SP, Hoang K, et al. (September 2016). "Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD)" . Drug Testing and Analysis . 8 (9): 891–902. doi :10.1002/dta.1884 . PMC 4829483 . PMID 26456305 .
^ Brandt SD, Kavanagh PV, Westphal F, Elliott SP, Wallach J, Colestock T, et al. (January 2017). "Return of the lysergamides. Part II: Analytical and behavioural characterization of N6 -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ)" . Drug Testing and Analysis . 9 (1): 38–50. doi :10.1002/dta.1985 . PMC 5411264 . PMID 27265891 .
^ Brandt SD, Kavanagh PV, Westphal F, Elliott SP, Wallach J, Stratford A, et al. (October 2017). "Return of the lysergamides. Part III: Analytical characterization of N6 -ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1-propionyl ETH-LAD (1P-ETH-LAD)" . Drug Testing and Analysis . 9 (10): 1641–1649. doi :10.1002/dta.2196 . PMC 6230477 . PMID 28342178 .
^ Brandt SD, Kavanagh PV, Twamley B, Westphal F, Elliott SP, Wallach J, et al. (February 2018). "Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775)" . Drug Testing and Analysis . 10 (2): 310–322. doi :10.1002/dta.2222 . PMC 6230476 . PMID 28585392 .
^ Brandt SD, Kavanagh PV, Westphal F, Stratford A, Elliott SP, Dowling G, et al. (August 2019). "Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD)" . Drug Testing and Analysis . 11 (8): 1122–1133. doi :10.1002/dta.2613 . PMC 6899222 . PMID 31083768 .
^ Halberstadt AL, Klein LM, Chatha M, Valenzuela LB, Stratford A, Wallach J, et al. (February 2019). "Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA)" . Psychopharmacology . 236 (2): 799–808. doi :10.1007/s00213-018-5055-9 . PMC 6848745 . PMID 30298278 .
^ Kruegel AC. Novel Ergolines and Methods of Treating Mood Disorders. Patent WO 2022/226408
^ WO 2022/008627 , Grill M, "Improved Method for the Production of Lysergic Acid Diethylamide (LSD) and Novel Derivatives thereof."
^ Brandt SD, Kavanagh PV, Westphal F, Stratford A, Odland AU, Klein AK, et al. (June 2020). "Return of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD)" . Drug Testing and Analysis . 12 (6): 812–826. doi :10.1002/dta.2789 . PMC 9191646 . PMID 32180350 .
^ Okada Y, Segawa H, Yamamuro T, Kuwayama K, Tsujikawa K, Kanamori T, et al. (June 2024). "Synthesis and analytical characterization of 1-(2-thienoyl)-6-allyl-nor-d-lysergic acid diethylamide (1T-AL-LAD)". Drug Testing and Analysis . doi :10.1002/dta.3747 . PMID 38922764 .
^ Usdin E, Efron DH. Psychotropic Drugs and Related Compounds. (1972) ASIN B002X3CDIY
^ WO 2021/076572 , Olson DE, et al., "Ergoline-like compounds for promoting neural plasticity"
^ Libânio Osório Marta RF (August 2019). "Metabolism of lysergic acid diethylamide (LSD): an update". Drug Metabolism Reviews . 51 (3): 378–387. doi :10.1080/03602532.2019.1638931 . PMID 31266388 .